Cargando…

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study

Baclofen, a racemic γ-aminobutyric acid B receptor agonist, is commonly used for the management of multiple sclerosis–related spasticity but is associated with frequent dosing and poor tolerability. Arbaclofen, the active R-enantiomer of baclofen, exhibits 100- to 1000-fold greater specificity for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuda, Darin T, Kantor, Daniel, Jaros, Mark, deVries, Tina, Hunter, Samuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968651/ https://www.ncbi.nlm.nih.gov/pubmed/36861013 http://dx.doi.org/10.1093/braincomms/fcad026

Ejemplares similares

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
por: Okuda, Darin T, et al.
Publicado: (2022)

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
por: deVries, Tina, et al.
Publicado: (2019)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

A MEG Study of Acute Arbaclofen (STX-209) Administration
por: Roberts, Timothy P. L., et al.
Publicado: (2019)

Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder
por: Frye, Richard E
Publicado: (2014)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang, Fu De, et al.
Publicado: (2017)

Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study
por: Glue, Paul, et al.
Publicado: (2020)

Additive Manufacturing of an Extended-Release Tablet of Tacrolimus
por: Abdollahi, Azin, et al.
Publicado: (2023)

Towards Preclinical Validation of Arbaclofen (R-baclofen) Treatment for 16p11.2 Deletion Syndrome
por: Gundersen, Brigitta B., et al.
Publicado: (2023)

Metoprolol succinate extended release/hydrochlorothiazide combination tablets
por: Hainer, James W, et al.
Publicado: (2007)

Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study
por: Wigal, Sharon B., et al.
Publicado: (2018)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
por: Jara, Michele, et al.
Publicado: (2014)

Useful Extend-release Chitosan Tablets with High Antioxidant Activity
por: Yasufuku, Taira, et al.
Publicado: (2010)

Development and bioequivalence study of potassium chloride extended release tablets
por: Le Thi, Thu Van, et al.
Publicado: (2018)

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets
por: Carapeto, Gustavo Vaiano, et al.
Publicado: (2023)

Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study
por: Samara, Emil, et al.
Publicado: (2014)

Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension
por: Weiss, Margaret D., et al.
Publicado: (2020)

Formulation Development and Stability Studies of Norfloxacin Extended-Release Matrix Tablets
por: Oliveira, Paulo Renato, et al.
Publicado: (2013)

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets
por: Milanowski, Bartłomiej, et al.
Publicado: (2020)

Arbaclofen Placarbil Decreases Reflux With Good Tolerability in Patients With Gastroesophageal Reflux Disease (Am J Gastroenterol 2010;105:1266-1275)
por: Kim, Gwang Ha
Publicado: (2010)

Formulation and Evaluation of Trimetazidine Dihydrochloride Extended Release Tablets by Melt Congealing Method
por: Javeer, S. D., et al.
Publicado: (2010)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013)

Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites
por: Anraku, Makoto, et al.
Publicado: (2019)

IVIVC for Extended Release Hydrophilic Matrix Tablets in Consideration of Biorelevant Mechanical Stress
por: Mohylyuk, Valentyn, et al.
Publicado: (2020)

Quantitative determination of related substances for Lamotrigine extended release tablet by RP-HPLC
por: Gondhale-Karpe, Priyanka, et al.
Publicado: (2023)

Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Formulation and in vitro Evaluation of Alfuzosin Extended Release Tablets Using Directly Compressible Eudragit
por: Roni, M. A., et al.
Publicado: (2009)

Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
por: Hawi, Amale, et al.
Publicado: (2015)

Assessing Palatability of a New Amphetamine Extended-Release Tablet Formulation for the Treatment of ADHD
por: Pardo, Antonio, et al.
Publicado: (2021)

Monolithic LC method applied to fesoterodine fumarate low dose extended-release tablets: Dissolution and release kinetics
por: Sangoi, Maximiliano S., et al.
Publicado: (2015)

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression
por: Kanba, Shigenobu, et al.
Publicado: (2019)

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Leg Spasticity and Ambulation in Multiple Sclerosis
por: Balantrapu, Swathi, et al.
Publicado: (2014)

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
por: Stuve, Olaf, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s64h3ao5hr4chriceo867dhjpo